Anyone who follows the fashion industry will know that New York City is the mecca of fashion in the U.S. New York Fashion Week is a huge event and platform every aspiring designer or model wants to be a part of. The exposure can easily launch an individual into limelight.
Finding a designer talented enough to make a name for themselves in the industry on a consistent basis can be beyond difficult. With that being said, the School of Fashion at the Academy of Art University aims to do just that. The institution held its 21st runway showcase in September at Skylight Clarkson Square.
Each collection debuted possesses the heart and soul of its designer. The show is full of various designs rooted in several different cultures which isn’t surprising considering the diverse background of the designers. Individuality is something the university strongly encourages as it brings a range of ideas and original creativity.
The academy also teaches students that being successful takes long hours of hard work. Hours and weeks of tough labor may only amount to 15 minutes worth of product. The ability to make it through the tough times to reach the good times is essential.
The Academy of Art University has been standing for nearly a century. Founded in 1929 in San Francisco, California today it boasts a student base well over 10,000 students. It is arguably the largest privately owned for-profit art school in the nation. It is an academy built by an artist for artists.
In 2005, it began participating in New York Fashion Week bi-annually. After it began participating in the event student numbers increased tremendously.
The academy is passionate about helping young people showcase their talents and achieve their dreams. Alumni look at the academy as a sanctuary for aspiring artists no matter their passion.
Amicus Therapeutics is a biotechnology company that focuses on researching treatment for rare and orphan diseases. Although the company is based in Cranbury, New Jersey, they operate a second research site in San Diego, California. Amicus was founded in 2002 but didn’t go public until 2007. The company is fairly small, with around five hundred employees. Amicus is primarily research based and has to have other companies take care of manufacturing. Although the company offers no products as of 2017, a few potential products are in the final stages of being approved for commercial use.
Fabry Disease is one illness that Amicus Therapeutics is currently researching. The company has developed two potential products to help treat it: Galafold/Migalastat Monotherapy and novel ERTs (Enzyme Replacement Therapy). Galafold is an orally administered monotherapy that has full approval in Europe and is ready to be released to the public. Migalastat Monotherapy and Galafold are one in the same, with Galafold being the brand name. While the product is ready for use in Europe, it is still in the approval stages in the Americas and the rest of the world. Amicus’ ERTs for Fabry Disease are in preclinical stages of research.
In addition to Fabry Disease, Amicus Therapeutics studies two other illnesses specifically, Pompe Disease and Epidermolysis Bullosa. Their product for Pompe Disease, a novel ERT named ATB200 and AT2221 are in the middle of the final phase of testing. This treatment will require a chaperone as well. Amicus’ medication for Epidermolysis Bullosa is named SD-101. It is a topical medication. Currently, SD-101 is in the third and final phase of testing.
While Amicus Therapeutics focuses on a few diseases specifically, they also conduct research on other rare diseases and plan treatments for patients with these illnesses. Most of their medications for these various diseases are novel ERTs and most of them are in the primary research phase of development.
Dedicated to research and creating treatments for those with rare illnesses, Amicus Therapeutics is a company to keep an eye on. Several products are nearing their final stages and are one step closer to helping others survive.
More here: Crunchbase
Eva Moskowitz is the CEO of Success Academy, and she has had a distinguished career in education that has brought her to this place. She is leading one of the finest educational companies in America, and she is putting together schools that will serve children well no matter their educational needs. This article explains how Eva has done the work that is required to grow this brand.
#1: Eva Moskowitz And Success Academy
Eva Moskowitz is known today for being the CEO of Success Academy, and she has spent decades in education working on many levels. She knows how to lead schools that will bring greater success to students, and she uses his public sector and private sector skill set to the table.
#2: What Does Success Academy Do?
Eva has set up Success Academy to offer personal instruction to the students who count on the school every day. They have opened many schools across America to serve kids who need an alternative education, and Eva often promotes the alternative education that these students needs. She knows that a child who is given a better education today at Success Academy will move on to greater things in the future.
#3: How Does Eva Advocate For Her Students?
Eva Moskowitz is a name that is known across the education industry for advocating on behalf of all students who need a better education. The students who come to her schools are there because they need to be taught in a new way, and Eva leaves the Success Academy open to as many new educational techniques as possible. She would rather help students learn in a new way than force them to learn in a manner that does not work for them.
The career of Eva Moskowitz is one that has made a difference in the lives of thousands of children. The Success Academy is touching lives every day as children learn more than they could have ever imagined in a building that suits them. These children may have the dream of college realized, and Eva will continue to grow this brand to help the alternative student.